An ovarian hyperstimulation syndrome caused by gonadotropinoma in a young woman

From 14 to 54% of all pituitary adenomas are nonfunctioning pituitary adenomas (NPAs), their prevalence is estimated as 7.0–41.3 cases per 100 000 population. The most common type of NPAs (73% of cases) are gonadotropinomas. In most cases, gonadotropinoma is characterized by secretion of biologically inactive hormones, so the release of gonadotropins does not lead to the development of any clinical symptoms. For this reason the diagnosis of gonadotropinomas is most often performed on the basis of immunohistochemical analysis. However, in rare cases, gonadotropinomas secrete biologically active hormones, most often follicle-stimulating (FSH). Ovarian hyperstimulation syndrome due to gonadotropin-secreting pituitary tumors occurs in about 3% of women with hormonally inactive pituitary adenomas at reproductive age and in 8% of patients with verified gonadotropinomas. This clinical case describes a young patient with a rare pathology: FSH/LH-secreting macroadenoma of the pituitary, which led to the development of ovary hyperstymulation symdrome. The diagnosis of pituitary adenoma was performed due to the identified hyperprolactinemia one month before the development of visual impairment, which can be considered a late diagnosis. Surgical treatment of gonadotropinomy was carried out successfully and without complications, remission of the disease was achieved, visual function was restored, the patient successfully became pregnant.

1. Katznelson L, Alexander JM, Klibanski A. Clinical review 45: clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 1993;76(5):1089–1094. doi: https://doi.org/10.1210/jcem.76.5.8496297.

2. Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary. 2018;21(2):111–118. doi: 10.1007/s11102-018-0869-3.

3. Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg. 2008;108(3):525–532. doi: https://doi.org/10.3171/JNS/2008/108/3/0525.

4. Nishioka H, Inoshita N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol. 2015;26(4):349–355. doi: https://doi.org/10.1007/s12022-015-9398-z.

5. Yamada S, Ohyama K, Taguchi M, et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery. 2007;61(3):580–585. doi: 10.1227/01.NEU.0000290906.53685.79.

6. Snyder PJ. Extensive personal experience: gonadotroph adenomas. J Clin Endocrinol Metab. 1995;80(4):1059–1061. doi: https://doi.org/10.1210/jcem.80.4.7714066.

7. Snyder PJ. Gonadotroph cell adenomas of the pituitary. Endocr Rev. 1985;6(4):552–563. doi: https://doi.org/10.1210/edrv-6-4-552.

8. Snyder PJ. Clinically nonfunctioning pituitary adenomas. Endocrinol Metab Clin North Am. 1993;22(1):163–175. doi: https://doi.org/10.1016/S0889-8529(18)30185-3.

9. Balinisteanu B, Ceausu RA, Cimpean AM, et al. Conventional examination versus immunohistochemistry in the prediction of hormone profile of pituitary adenomas. An analysis on 142 cases. Rom J Morphol Embryol. 2011;52(3 Suppl):1041–1045.

10. Ntali G, Capatina C, Grossman A, Karavitaki N. Clinical review: functioning gonadotroph adenomas. J Clin Endocrinol Metab. 2014;99(12):4423–4433. doi: https://doi.org/10.1210/jc.2014-2362.

11. Chamoun R, Layfield L, Couldwell WT. Gonadotroph adenoma with secondary hypersecretion of testosterone. World Neurosurg. 2013;80(6):900.e7-11. doi: https://doi.org/10.1016/j.wneu.2012.11.069.

12. Kumar P, Bishnoi I, Singh D, et al. Follicle stimulating hormone secreting pituitary macroadenoma in males: a rare entity. Neurol India. 2016;64(5):1068–1071. doi: https://doi.org/10.4103/0028-3886.190225.

13. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377–382. doi: https://doi.org/10.1111/j.1365-2265.2009.03667.x.

14. Broughton C, Mears J, Williams A, Lonnen K. A clinically functioning gonadotroph adenoma presenting with abdominal pain, ovarian hyperstimulation and fibromatosis. Endocrinol Diabetes Metab Case Rep. 2018;2018:EDM180123. doi: https://doi.org/10.1530/EDM-18-0123.

15. Caretto A, Lanzi R, Piani C, et al. Ovarian hyperstimulation syndrome due to follicle-stimulating hormone-secreting pituitary adenomas. Pituitary. 2017;20(5):553–560. doi: https://doi.org/10.1007/s11102-017-0817-7.

16. Cote DJ, Smith TR, Sandler CN, et al. Functional gonadotroph adenomas: case series and report of literature. Neurosurgery. 2016;79(6):823–831. doi: https://doi.org/10.1227/NEU.0000000000001188.

17. Graillon T, Castinetti F, Chabert-Orsini V, et al. Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: a new emergency in pituitary adenoma surgery? Surgical considerations and literature review. Ann Endocrinol (Paris). 2019;80(2):122–127. doi: https://doi.org/10.1016/j.ando.2018.11.007.

18. Halupczok J, Bidzińska-Speichert B, Lenarcik-Kabza A, et al. Gonadotroph adenoma causing ovarian hyperstimulation syndrome in a premenopausal woman. Gynecol Endocrinol. 2014;30(11):774–777. doi: https://doi.org/10.3109/09513590.2014.934668.

19. Panagiotopoulou N, Byers H, Newman WG, Bhatia K. Spontaneous ovarian hyperstimulation syndrome: case report, pathophysiological classification and diagnostic algorithm. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):143–148. doi: https://doi.org/10.1016/j.ejogrb.2013.03.004.

20. Tatsuoka H, Inano S, Hamamoto Y, et al. Male gonadotroph adenoma: report of three cases and a review of the literature. Intern med. 2013;52(11):1199–1202.doi: https://doi.org/10.2169/internalmedicine.52.7855.

21. Kawaguchi T, Ogawa Y, Ito K, et al. Follicle-stimulating hormone-secreting pituitary adenoma manifesting as recurrent ovarian cysts in a young woman – latent risk of unidentified ovarian hyperstimulation: a case report. BMC Res Notes. 2013;6:408.doi: https://doi.org/10.1186/1756-0500-6-408.

22. Halupczok J, Kluba-Szyszka A, Bidzinska-Speichert B, et al. hyperstimulation caused by gonadotroph pituitary adenoma – review. Adv Clin Exp Med. 2015;24(4):695–703.doi: https://doi.org/10.17219/acem/25212.

23. Andino-Rios GG, Portocarrero-Ortiz L, Rojas-Guerrero C, et al. Nonfunctioning pituitary adenoma that changed to a functional gonadotropinoma. Case Rep Endocrinol. 2018;2018:5027859.doi: https://doi.org/10.1155/2018/5027859.

24. Karapanou O, Tzanela M, Tamouridis N, Tsagarakis S. Gonadotroph pituitary macroadenoma inducing ovarian hyperstimulation syndrome: successful response to octreotide therapy. Hormones (Athens). 2012;11(2):199–202.doi: https://doi.org/10.14310/horm.2002.1347.

25. Leese G, Jeffreys R, Vora J. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone. Postgrad Med J. 1997;73(862):507–508.doi: https://doi.org/10.1136/pgmj.73.862.507.

26. Miras AD, Mogford JT, Wright J, et al. Ovarian hyperstimulation from ectopic hypersecretion of follicle stimulating hormone. Lancet. 2015;385(9965):392.doi: https://doi.org/10.1016/S0140-6736(14)62294-7.

27. Schubert RL, Narayan P, Puett D. Specificity of cognate ligand-receptor interactions: fusion proteins of human chorionic gonadotropin and the heptahelical receptors for human luteinizing hormone, thyroid-stimulating hormone, and follicle-stimulating hormone. Endocrinology. 2003;144(1):129–137. doi: 10.1210/en.2002-220829.

28. Smits G, Campillo M, Govaerts C, et al. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J. 2003;22(11):2692–2703.doi: https://doi.org/10.1093/emboj/cdg260.

29. De Leener A, Montanelli L, Van Durme J, et al. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab. 2006;91(2):555–562. doi: 10.1210/jc.2005-1580.

30. Montanelli L, Delbaere A, Di Carlo C, et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2004;89(4):1255–1258.doi: https://doi.org/10.1210/jc.2003-031910.

31. Smits G, Olatunbosun O, Delbaere A, et al. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med. 2003;349(8):760–766.doi: https://doi.org/10.1056/NEJMoa030064.

32. Vasseur C, Rodien P, Beau I, et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med. 2003;349(8):753–759.doi: https://doi.org/10.1056/NEJMoa030065.

33. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.doi: https://doi.org/10.1038/nrdp.2016.57.

34. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.doi: https://doi.org/10.1186/1741-7015-8-41.

35. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618.doi: https://doi.org/10.1016/j.fertnstert.2018.05.004.

36. Givens V, Mitchell GE, Harraway-Smith C, et al. Diagnosis and management of adnexal masses. Am Fam Physician. 2009;80(8): 815–820.

37. Письмо Министерства здравоохранения РФ от 04.12.18 №15-4/10/2-7838 «Диагностика и лечение доброкачественных новообразований яичников с позиции профилактики рака» [интернет]. [Letter of Ministry of Health of the Russian Federation dated December 4, 2018, № 15-4/10/2-7838 «Diagnostika i lechenie dobrokachestvennykh novoobrazovanii yaichnikov s pozitsii profilaktiki raka» [internet]. (In Russ).] Доступно по: https://primorsky.ru/authorities/executive-agencies/departments/health/klinicheskie-protokoly-po-akusherstvu-i-ginekologii/. Ссылка активна на 15.04.2019.

38. Дедов И.И., Мельниченко Г.А., Рожинская Л.Я., и др. Инциденталомы гипофиза: клиника, диагностика, дифференциальная диагностика и методы лечения // Проблемы эндокринологии. – 2015. Т. 61. – №3 – С. 57–68. [Dedov II, Melnichenko GA, Rozhinskaya LYa, et al. Pituitary incidentalomas: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problems of endocrinology. 2015;61(3):57–68. (In Russ).] doi: https://doi.org/10.14341/probl201561357-68.